Market Synopsis

The antibody drug conjugate market was worth USD 1.98 billion in 2021 and is expected to rise from USD 2.31 billion in 2022 to USD 6.81 billion by 2030, with a compound annual growth rate (CAGR) of 16.70% over the forecast period (2022- 2030).

According to Market Research Future (MRFR), the worldwide antibody drug conjugate market is expected to grow significantly over the forecast period. It is a new application that combines the unique, high specificity, properties, and antitumor activity of monoclonal antibodies.

The global antibody drug conjugate market in 2020 is rapidly expanding due to an increase in the number of cancer patients. The therapy is effective in treating a variety of cancers, including breast and endometrial cancer. Breast cancer is one of the most common types of cancer that affects women. According to WHO statistics, 15% of women worldwide died from breast cancer in 2015. Furthermore, growing awareness of antibody-based treatment is boosting the market. Furthermore, the growing population is expected to have a significant impact on the industry. Furthermore, advancements in the medical industry are propelling the market significantly. The growing obese and geriatric population is expected to significantly boost the market throughout the forecast decade.

On the contrary, the high cost of procedures and insufficient funding are expected to impede market expansion. However, expanding research and development initiatives, preclinical research, and increased collaboration amongst research institutes are expected to fight the limiting limitations.

The antibody drug conjugate market is witnessing substantial growth due to rising demand for targeted cancer therapies. These innovative treatments combine monoclonal antibodies with cytotoxic agents, delivering potent anti-cancer activity. Advancements in biotechnology and increasing research investments are driving market expansion, offering new hope for patients with challenging malignancies.

Market Segmentation

The segment analysis of the global antibody drug conjugate market is based on type, product, technology, application, and end-user.

The type-based segments of the global antibody drug conjugate market are linker, drug/toxin, monoclonal antibodies, and others.

The product-based segments of the global antibody drug conjugate market are Kadcyla, Adcertis, and others.

The technology-based segments of the global antibody drug conjugate market are Seattle Genetics technology, ImmunoGen technology, Immunomedics technology, and others.

The application-based segments of the global antibody drug conjugate market are prostate cancer, leukemia, kidney cancer, ovary cancer, pancreas cancer, glioblastoma, colon cancer, lung cancer, breast cancer, solid tumors, skin cancer, multiple myeloma, lymphoma, and other cancers

The end-user-based segments of the global antibody drug conjugate market are specialized cancer centers, hospitals, academic research institutes, biopharmaceutical companies, biotechnology companies, and others. 

Regional Analysis

Based on the region, the global antibody drug conjugate market is segmented into America, Europe, Asia-Pacific, and the Middle East and Africa. As per the research, the global market is estimated to be commanded by the Americas due to technological innovation, development in the manufacturing method, and the participation of nanotechnology for developing Antibody Drug Conjugates (ADC). In the region, the US is recognized to acquire the largest market among other countries such as Canada and Mexico.

Europe is expected to acquire the second position. It is expected to be one of the most lucrative markets due to a large number of cancer patients in the region. Further, the participation of the government is estimated to fuel the market further.

The APAC region is projected to acquire a substantial market share during the forecast period. Countries like India and China are expected to be the fastest-growing region owing to the fast adoption of technology, larger population suffering from cancer, and the development of healthcare infrastructure.

The MEA region is estimated to procure the least amount of market share during the forecast period. The region is lagging owing to the presence of a poor economy. However, increasing awareness about health is likely to propel the market in the region.

Key Players

 The renowned players of the global antibody drug conjugate market   ImmunoGen, Inc. (US), Seattle Genetics (US), Roche Holding AG (Switzerland), Concortis Biotherapeutics (US), Genentech (US), Agensys, Inc. (US), Immunomedics (US), Antikor (UK), and Pfizer Inc. (US).

For more information visit at MarketResearchFuture